Understanding ADCETRIS: A Breakthrough in Lymphoma Treatment

ADCETRIS (brentuximab vedotin) represents a significant advancement in cancer treatment, specifically designed for patients with CD30-positive lymphomas. This targeted therapy combines a monoclonal antibody with a cytotoxic agent, delivering treatment directly to cancer cells while minimizing damage to healthy tissue.

**How ADCETRIS Works**

ADCETRIS uses antibody-drug conjugate (ADC) technology to target CD30, a protein found on the surface of certain lymphoma cells. Once attached, the drug releases its cytotoxic payload inside the cancer cell, leading to cell death.

**Approved Indications**

- Hodgkin lymphoma (after failed stem cell transplant or as consolidation therapy)
- Systemic anaplastic large cell lymphoma (sALCL)
- CD30-expressing peripheral T-cell lymphomas (PTCL)
- Primary cutaneous anaplastic large cell lymphoma (pcALCL)

**Treatment Benefits**

Clinical trials have shown ADCETRIS significantly improves progression-free survival and overall response rates compared to traditional chemotherapy. Patients experience fewer side effects due to its targeted mechanism.

**Administration**

ADCETRIS is administered intravenously every 3 weeks. Your oncologist will determine the appropriate dosage based on your specific condition and weight.

**Important Considerations**

Common side effects include peripheral neuropathy, fatigue, nausea, and neutropenia. Regular monitoring by your healthcare team is essential during treatment.

For more information about ADCETRIS dosing and availability, consult with your oncologist or contact our pharmaceutical specialists.